****** DATA-MÉDICOS *********

********************************* 

EL IMIQUIMOD II / THE IMIQUIMOD II

**************************************

***** DERMAGIC-EXPRESS No 8 *****

****** 22 OCTUBRE DE 1.998 ******* 

************************************

************************************

EDITORIAL ESPAÑOL:

===================

Hola de nuevo amigos Dermágicos, El Dr Gustavo Beltrán (Peru) , me envía una excelente MONOGRAFÍA del producto IMIQUIMOD, que la libero hoy para complementar los conocimientos sobre este nuevo producto.

Saludos a todos...

Próxima edición: LA TALIDOMIDA, EL REGRESO...

================================================================

DERMAGIC/EXPRESS(8)

================================================================

E L  I M I Q U I M O D II / THE IMIQUIMOD II

================================================================

DRUG EVALUATION MONOGRAPHS

Topic: IMIQUIMOD

0.0 OVERVIEW 

A. Imiquimod is an immune response modifier. 

B. DOSING INFORMATION: For the treatment of external 

genital/perianal warts (venereal warts; condyloma 

acuminata), a thin layer of imiquimod 5% cream is applied

to the warts 3 times a week until there is total 

clearance of the lesions or for a maximum of 16 weeks. 

C. PHARMACOKINETICS: The pharmacokinetics of imiquimod have

not been extensively studied; percutaneous absorption is 

minimal. Less than 0.9% of a radiolabeled dose of 

imiquimod is excreted in the urine and feces after 

topical application. It is not known whether topically 

applied imiquimod is excreted into breast milk. 

D. CAUTIONS: Local skin reactions including erythema, 

erosion, excoriation, flaking, and edema are the most 

common adverse effects of topical imiquimod; therapy 

should be temporarily discontinued until local effects 

subside. Imiquimod has not been evaluated for the 

treatment of urethral, intravaginal, cervical, rectal, or

intraanal human papillomavirus disease and is not 

recommended for these conditions. The safety and 

efficacy of imiquimod has not been determined in 

pediatric or pregnant patients. Topical imiquimod is not

for ophthalmic use. 

E. CLINICAL APPLICATIONS: Imiquimod 5% topical cream is 

useful for the treatment of external genital and perianal

warts (condyloma acuminata) in adults. However, 

comparative data are needed. Oral imiquimod has been 

used for the treatment of HIV disease or cancer; more 

safety and efficacy data are needed. 

1.0 DOSING INFORMATION 

1.1 DOSAGE FORMS 

A. Information on specific dosage forms can be obtained by 

entering a brand name or trade name at the "Type In 

Topic" screen or by choosing "ProdIndx". 

B. Imiquimod is manufactured in the US by 3M 

Pharmaceuticals as a 5% topical cream (Aldara(R)). 

C. SYNONYMS 

1. R-837 

2. S26308 

1.2 STORAGE AND STABILITY 

A. TOPICAL 

1. Imiquimod 5% topical cream should not be stored above 

30 degrees Centigrade; the product should not be 

allowed to freeze (Prod Info Aldara(R), 1997). 

1.3 ADULT DOSAGE 

1.3.1 NORMAL DOSE 

A. ADMINISTRATION TECHNIQUE 

1. Proper administration technique should be demonstrated 

DRUG EVALUATION MONOGRAPHS

Topic: IMIQUIMOD

by the prescriber to maximize the benefit of imiquimod 

therapy. Handwashing before and after application is 

recommended. Aldara(R) cream is packaged in single-use

packets which contain sufficient cream to cover a wart 

area of up to 20 square centimeters; use of excessive 

cream should be avoided. Patients should be instructed

to apply a thin layer of cream to the warts, and to rub

in the cream until it is no longer visible. The 

application site is not to be occluded (Prod Info 

Aldara(R), 1997). 

B. TOPICAL 

1. In the treatment of external genital or perianal warts 

(VENEREAL WARTS; CONDYLOMA ACUMINATA) in patients 

18 years of age or older, topical imiquimod 5 percent 

cream (Aldara(R)) is to be applied 3 times a week, 

prior to normal sleeping hours, and left on the skin 

for 6 to 10 hours. Following each treatment period, 

the cream should be removed by washing the treated area

with soap and water. Examples of 3 times per week 

application schedules are: Monday, Wednesday, Friday 

or Tuesday, Thursday, Saturday. Treatment should 

continue until there is total clearance of the 

genital/perianal warts, or for a maximum of 16 weeks 

(Prod Info Aldara(R), 1997). 

2. This topical regimen has shown efficacy in a controlled

trial (Beutner et al, 1994). 

3. Local skin reactions (erythema) are common; a rest 

period of several days may be taken if needed due to 

patient discomfort or the severity of the local skin 

reaction. Treatment may resume once the reaction 

subsides. Nonocclusive dressings such as cotton gauze 

or cotton underwear may be used in the management of 

skin reactions (Prod Info Aldara(R), 1997). 

1.4 PEDIATRIC DOSAGE 

1.4.1 NORMAL DOSE 

A. The safety and efficacy of imiquimod in patients below 

the age of 18 have not been studied (Prod Info 

Aldara(R), 1997). 

2.0 PHARMACOKINETICS 

2.3 ADME 

2.3.1 ABSORPTION 

A. TOPICAL, minimal (Prod Info Aldara(R), 1997). 

1. No radioactivity was detected in the serum (lower limit

of quantitation: 1 ng/mL) (Prod Info Aldara(R), 1997).

2.3.4 EXCRETION 

2.3.4.1 BREAST MILK 

A. BREASTFEEDING: Unknown (Prod Info Aldara(R), 1997). 

2.3.4.2 KIDNEY 

A. RENAL EXCRETION: Less than 0.9% (Prod Info Aldara(R), 

DRUG EVALUATION MONOGRAPHS

Topic: IMIQUIMOD

1997). 

2.3.4.3 OTHER 

A. FECES: Less than 0.9% (Prod Info Aldara(R), 1997). 

3.0 CAUTIONS 

3.1 CONTRAINDICATIONS 

A. Previous hypersensitivity to imiquimod 

3.2 PRECAUTIONS 

A. Imiquimod has not been evaluated for the treatment of 

urethral, intravaginal, cervical, rectal, or intraanal 

human papillomavirus disease and is not recommended for 

these conditions. 

B. Pediatric patients (the safety and efficacy of imiquimod

in patients below the age of 18 have not been studied) 

C. Topical imiquimod is not for ophthalmic use. 

D. Local skin reactions, including erythema, erosion, 

excoriation, flaking, and edema are common. If severe 

local skin reactions occur, the cream should be removed 

by washing the treatment area with soap and water. 

Treatment can be resumed after the reaction has 

subsided. 

E. There is no clinical experience with topical imiquimod 

therapy immediately following treatment with other 

cutaneously applied drugs; therefore, topical imiquimod 

administration is not recommended until genital/perianal

tissue is healed from any previous drug or surgical 

treatment. 

F. Topical imiquimod has the potential to exacerbate 

inflammatory conditions of the skin. 

3.3 ADVERSE REACTIONS 

3.3.3 CENTRAL NERVOUS SYSTEM 

A. CENTRAL NERVOUS SYSTEM EFFECTS 

1. HEADACHE has been reported in patients receiving 

topical imiquimod (Prod Info Aldara(R), 1997); however,

a causal relationship has not been determined. 

3.3.5 GASTROINTESTINAL 

A. GASTROINTESTINAL EFFECTS 

1. DIARRHEA has been reported with topical imiquimod (Prod

Info Aldara(R), 1997); however, a causal relationship 

has not been determined. 

3.3.10 SKIN 

A. DERMATOLOGIC EFFECTS 

1. SUMMARY: Local skin reactions including ERYTHEMA, 

EROSION, EXCORIATION, FLAKING, and EDEMA are common 

with imiquimod 5% cream (Prod Info Aldara(R), 1997). 

but the incidence of systemic reactions was similar to 

that observed with placebo (Beutner et al, 1994; Prod 

Info Aldara(R), 1997). 

3.3.11 MUSCULOSKELETAL 

A. MUSCULOSKELETAL EFFECTS 

DRUG EVALUATION MONOGRAPHS

Topic: IMIQUIMOD

1. MYALGIAS and FLU-LIKE SYMPTOMS have been reported with 

topical imiquimod (Prod Info Aldara(R), 1997); however,

a causal relationship has not been determined. 

3.3.12 OTHER 

A. ADVERSE EFFECTS - GENERAL 

1. Fatigue, malaise, vomiting, mood changes, and 

hypotension were dose-limiting toxicities in AIDS 

patients treated with weekly oral doses of imiquimod 

200 to 500 milligrams. Four of 12 patients who entered

into a maintenance treatment phase withdrew because of 

malaise (2 patients) or grade 3 hepatotoxicity 

(2 patients) (Goldstein et al, 1994). 

2. In another trial, administration of oral imiquimod 

100 to 500 milligrams once a week or 200 or 300 mg 

twice a week resulted in dose-limiting toxicities 

including fatigue, vomiting, chills and headache (Witt 

et al, 1993). 

B. CARCINOGENIC EFFECTS 

1. Rodent carcinogenicity data are not available. 

Imiquimod had no effect in a series of 8 different 

mutagenicity assays including Ames, mouse lymphoma, 

Chinese hamster ovary chromosome aberration, SHE cell 

transformation, rat and hamster bone marrow 

cytogenetics, and mouse dominant lethal test. Daily 

oral administration of imiquimod in rats at doses up to

8 times the recommended human dose on a mg/m(2) basis 

throughout mating, gestation, parturition, and 

lactation demonstrated no impairment of reproduction 

(Prod Info Aldara(R), 1997). 

3.4 TERATOGENICITY/EFFECTS IN PREGNANCY 

A. TERATOGENICITY 

1. Imiquimod 5% topical cream is classified as FDA Pregnancy

Category B by the manufacturer (Prod Info Aldara(R), 

1997). 

See Drug Consult reference: "PREGNANCY RISK CATEGORIES"

2. There are no studies of topical imiquimod in pregnant 

women. Imiquimod was not found to be rat or rabbit 

teratology studies. In rats at high maternally toxic 

doses (28 times the human dose on a mg/m(2) basis), 

reduced pup weights and delayed ossification were 

observed. In developmental studies with offspring of 

pregnant rats treated with imiquimod (8 times human 

dose), no adverse effects were demonstrated (Prod Info 

Aldara(R), 1997). 

4.0 CLINICAL APPLICATIONS 

4.1 MONITORING PARAMETERS 

4.1.1 THERAPEUTIC 

A. PHYSICAL EXAMINATION 

1. Reduction in wart size is indicative of a therapeutic 

DRUG EVALUATION MONOGRAPHS

Topic: IMIQUIMOD

response to imiquimod. 

4.1.2 TOXIC 

A. PHYSICAL EXAMINATION 

1. Patients receiving topical imiquimod should be 

monitored for signs and symptoms of hypersensitivity to

it. 

4.2 PATIENT INSTRUCTIONS 

IMIQUIMOD (i-mi-KWI-mod) (For the skin): 

- Treats genital warts. 

BRAND NAME(S): Aldara(R) 

WHEN YOU SHOULD NOT TAKE THIS MEDICINE: 

- Do not use this medicine if you have had an allergic 

reaction to imiquimod. 

HOW TO TAKE AND STORE THIS MEDICINE 

Cream: 

- Your doctor will tell you how much medicine to use 

and how often. You may be told to use the cream 3 

times each week (Monday-Wednesday- Friday OR Tuesday- 

Thursday-Saturday) right before you go to bed. 

- Keep using the cream until the warts are gone or up 

to 16 weeks. If you still have the warts after 16 

weeks, talk with your doctor. 

- Use the cream only on your skin. Do not get the 

medicine in your eyes. Do not use the medicine inside 

your vagina or anus. 

- Wash your hands with soap and water before and after 

you use this medicine. 

- Put a thin layer of cream over the warts and gently 

rub the cream into your skin. 

- Do not bandage or tightly wrap the area so that air 

cannot get to it. You may use gauze over the area, or 

wear cotton underwear. 

- Leave the cream on for 6-to-10 hours. Then wash the 

cream off using a mild soap and water. 

- Store the cream at room temperature away from heat 

and moisture. Do not freeze. 

- Keep all medicine out of the reach of children. 

If you miss a dose: 

- Use the medicine as soon as possible, unless it is 

almost time for your next dose. 

- Skip the missed dose if it is almost time for your 

next regular dose. 

- Do not put on two doses at the same time. 

DRUGS AND FOODS TO AVOID: 

Ask your doctor or pharmacist before taking any other 

medicine, including over-the counter products. 

WARNINGS: 

- If you are pregnant or breastfeeding, talk to your 

DRUG EVALUATION MONOGRAPHS

Topic: IMIQUIMOD

doctor before using this medicine. 

- Do not have sex while being treated for warts, even 

if you or your partner are using a condom. The cream 

can weaken condoms and diaphragms, so you and your 

partner may be unprotected during sex. 

- Imiquimod is not a cure for genital or anal warts, so 

you may develop new warts while using the cream. 

SIDE EFFECTS 

Call your doctor right away if you have any of these side 

effects: 

- Severe skin burning, pain, or peeling 

- Open sores where you use the medicine 

If you have problems with these less serious side effects, 

talk with your doctor: 

- Mild skin redness, swelling, flaking, or dryness 

- Itching 

- Headache, muscle pain, or feeling like you have the 

flu 

IF YOU HAVE OTHER SIDE EFFECTS THAT YOU THINK ARE CAUSED 

BY THIS MEDICINE, TELL YOUR DOCTOR 

4.3 PLACE IN THERAPY 

A. Imiquimod topical cream appears to be safe and effective

for the treatment of condyloma acuminata. As an immune 

response modifier, imiquimod represents a new 

therapeutic approach to the treatment of this disease. 

Other available treatments for genital warts have 

included chemical burn, loop electrocautery excision, 

surgery, laser excision, cryotherapy, intralesional 

interferon, and tissue-destructive drugs such as 

podofilox and podophyllin. Imiquimod may offer 

increased patient comfort and compliance, and may 

encourage the patient to seek medical treatment. 

However, more comparative data are needed to assess the 

place of imiquimod in therapy. 

B. Imiquimod has been used in early clinical trials for the

treatment of cancer and AIDS. However, data are 

extremely limited, and more clinical trials are needed. 

Phase I trials have reported little or no antineoplastic

activity, and significant toxicity, of oral imiquimod. 

4.4 MECHANISM OF ACTION/PHARMACOLOGY 

A. MECHANISM OF ACTION 

1. The mechanism of action of imiquimod in the treatment 

of genital and perianal warts is unknown. Imiquimod 

has no direct antiviral activity in cell culture. 

Mouse skin studies suggest that imiquimod induces 

cytokines including interferon-alpha. However, the 

clinical relevance of these findings is unknown (Prod 

Info Aldara(R), 1997). 

2. In one study, serum interferon-alpha levels were 

DRUG EVALUATION MONOGRAPHS

Topic: IMIQUIMOD

induced after oral administration of imiquimod 

100 to 500mg once a week and 200 or 300 mg twice a week

to patients with cancer. Significant increases in 

serum beta-2 microglobulin, serum neopterin, and 2-5A 

synthetase activity in peripheral blood mononuclear 

cells were also observed (Witt et al, 1993). 

B. PRECLINICAL PHARMACOLOGY 

1. Oral treatment of mice with imiquimod 30 mg/kg every 

3 days significantly inhibited the growth of MC-26 

colon carcinoma. An antiserum to murine 

interferon-alpha significantly inhibited the antitumor 

effects of imiquimod, suggesting that these effects 

were mediated by interferon induction. Imiquimod also 

significantly reduced the number of lung colonies in 

mice inoculated with MC-26 tumor cells. Imiquimod plus

cyclophosphamide resulted in significantly better 

responses than either drug alone and led to cures in 

some of the mice inoculated with either subcutaneous or

intravenous MC-26 cells. Imiquimod treatment also 

resulted in tumor growth inhibition in mice with RIF-1 

sarcoma and Lewis lung carcinoma, but was not effective

in P388 leukemia (Sidky et al, 1992). 

2. Imiquimod has been shown to be a direct B cell mitogen 

in vitro. In one study, it induced the proliferation 

of murine B cells in a dose-dependent manner; it also 

induced IgM secretion from resting B cells. This 

effect was enhanced by the addition of interferon-gamma

(Tygrett et al, 1996). 

3. Other studies have shown imiquimod to be an inducer of 

several cytokines, including interferons and tumor 

necrosis factor in human lymphocytes, monocytes, and 

keratinocytes in vitro (Testerman et al, 1995; Gibson 

et al, 1995; Kono et al, 1994; Megyeri et al, 1995; 

Weeks & Gibson, 1994). 

C. REVIEW ARTICLES 

1. A review of various approaches to immunomodulation, 

including imiquimod, is available (Johnson, 1994). 

2. A review of antiviral agents in dermatology, including 

imiquimod, is provided (Memar & Tyring, 1995). 

4.5 THERAPEUTIC USES 

A. AIDS 

1. OVERVIEW 

FDA APPROVAL: Adult, no; pediatric, no 

EFFICACY: Adult, possibly effective 

DOCUMENTATION: Adult, poor 

2. SUMMARY: Oral imiquimod has not been extensively 

studied in the treatment of HUMAN IMMUNODEFICIENCY 

VIRUS INFECTION. 

3. ADULT: 

DRUG EVALUATION MONOGRAPHS

Topic: IMIQUIMOD

a. Significant rises in serum interferon, beta-2 

microglobulin, and neopterin levels were observed with

weekly oral doses of imiquimod of more than 100 

milligrams in a phase I study of 12 patients with 

asymptomatic HIV INFECTION. CD4 counts increased by a

median of 13% at week 1 and 20% at week 9. Fatigue, 

malaise, vomiting, mood changes, and hypotension were 

dose-limiting toxicities in patients treated with 

weekly doses of 200 to 500 milligrams. Four of 12 

patients who entered into a maintenance treatment 

phase withdrew because of malaise (2 patients) or 

grade 3 hepatotoxicity (2 patients) (Goldstein et al, 

1994). 

B. CANCER 

1. OVERVIEW 

FDA APPROVAL: Adult, no; pediatric, no 

EFFICACY: Adult, possibly effective 

DOCUMENTATION: Adult, poor 

2. SUMMARY: Oral imiquimod has not been extensively 

studied in the treatment of cancer. Small trials have 

achieved little or no beneficial activity with oral 

imiquimod. 

3. ADULT: 

a. No antitumor activity was observed in one phase I 

study involving 14 patients with cancer who received 

oral imiquimod 100 to 500 milligrams (mg) once a week 

or 200 or 300 mg twice a week. Dose-limiting 

toxicities included fatigue, vomiting, chills and 

headache (Witt et al, 1993). 

b. A mixed response was observed in 1 of 21 patients with

refractory cancer in a phase I trial. Patients 

received oral imiquimod 25, 50, 100 or 200 mg once 

daily for a projected 112-day course. Only 3 patients

completed the course, all receiving 50 mg day. 

Toxicity was dose- related, and consisted primarily of

flu-like symptoms, nausea, and lymphopenia. In the 

patient with a mixed response, biological activity was

confirmed by significant and sustained elevations in 

peripheral blood mononuclear cell 2-5 synthetase 

levels at all doses, and elevations in neopterin, 

beta-2-microglobulin, and interferon levels (Savage et

al, 1996). 

C. CONDYLOMA ACUMINATA 

FDA Labeled Indication 

1. OVERVIEW 

FDA APPROVAL: Adult, yes; pediatric, no 

EFFICACY: Adult, effective 

DOCUMENTATION: Adult, excellent 

2. SUMMARY: Imiquimod 5% topical cream is effective for 

DRUG EVALUATION MONOGRAPHS

Topic: IMIQUIMOD

the treatment of external genital and perianal warts 

(VENEREAL WARTS) in adults, with a 40% to 56% complete 

clearance of warts, a reduction in the recurrence rate.

Topical imiquimod 5% cream is to be applied 3 times a 

week and left on the skin for 6 to 10 hours (Prod Info 

Aldara(R), 1997). 

3. ADULT: 

a. Imiquimod 5% cream is more effective than placebo in 

108 patients with genital or perianal warts due to 

HUMAN PAPILLOMAVIRUS INFECTION. In this randomized, 

double-blind study, patients received either imiquimod

cream or placebo 3 times weekly for up to 8 weeks. 

Median wart area was reduced by 90% with a 40% 

complete wart clearance in patients receiving 

imiquimod, compared to no patients receiving placebo. 

During a 10-week follow-up period, 81% of patients 

receiving imiquimod had no recurrence of disease 

(Beutner et al, 1994). 

b. In another randomized, multicenter, double-blind study

of 311 patients with genital or perianal warts, warts 

cleared in 56% of patients receiving imiquimod 5% 

cream, in 27% patients receiving imiquimod 1%, and in 

14% of patients receiving placebo. Clearance rates 

for imiquimod 5% cream were 77% in females and 40% in 

males; there were no significant differences in 

recurrence rates (Edwards et al, 1995). 

c. In another trial, patients receiving 5% topical 

imiquimod cream experienced a 90% reduction in wart 

area; 40% of patients receiving imiquimod had complete

clearance of warts, compared to no patients receiving 

placebo (vehicle). Although imiquimod caused more 

local skin irritation than placebo, no systemic 

effects were reported (Spruance et al, 1993). 

6.0 REFERENCES 

1. Beutner K, Spruance S, Douglas J et al: Double-blind, 

vehicle controlled, randomized, multicenter trial of 5% 

imiquimod cream for the treatment of genital and perianal

warts (abstract). Second Int Cong Papillomavirus Human 

Pathol 1994; 93. 

2. Edwards L, Ferenczy A, Eron L et al: Multi-center safety

and efficacy trial evaluating three times per week 

application of 1% and 5% topical imiquimod for the 

treatment of genital/perianal warts (abstract). 

Antiviral Research 1995; 26:A244. 

3. Gibson SJ, Imbertson LM, Wagner TL et al: Cellular 

requirements for cytokine production in response to the 

immunomodulators imiquimod and S-27609. J Interferon 

Cytokine Res 1995; 15:537-545. 

4. Goldstein D, Tomkinson E, Couldwell D et al: Phase I A/B

DRUG EVALUATION MONOGRAPHS

Topic: IMIQUIMOD

trial of imiquimod, an oral interferon inducer in 

asymptomatic HIV positive individuals (abstract). AIDS 

1994; 8(Suppl):14. 

5. Johnson AG: Molecular adjuvants and immunomodulators: 

new approaches to immunization. Clin Microbiol Reviews 

1994; 7:277-289. 

6. Kono T, Kondo S, Pastore S et al: Effects of a novel 

topical immunomodulator, imiquimod, on keratinocyte 

cytokine gene expression. Lymphokine Cytokine Res 1994; 

13:71-76. 

7. Megyeri K, Au WC, Rosztoczy I et al: Stimulation of 

interferon and cytokine gene expression by imiquimod and 

stimulation by Sendai virus utilize similar signal 

transduction pathways. Molec Cell Biol 1995; 

15:2207-2218. 

8. Memar OM & Tyring SK: Antiviral agents in dermatology: 

current status and future prospects. Int J Dermatol 

1995; 14:597-606. 

9. Product Information: Aldara(R), imiquimod 5% cream. 3M 

Pharmaceuticals, Northridge, CA, 1997. 

10. Savage P, Horton V, Moore J et al: A phase I clinical 

trial of imiquimod, an oral interferon inducer, 

administered daily. Br J Cancer 1996; 74:1482-1486. 

11. Sidky YA, Borden EC, Weeks CE et al: Inhibition of 

murine tumor growth by an interferon-inducing 

imidazoquinolinamine. Cancer Res, 1992; 52:3528-3533. 

12. Spruance S, Douglas J, Hougham A et al: Multicenter 

trial of 5% imiquimod (IQ) cream for treatment of 

genital and perianal warts (abstract). Prog Abstr 33rd 

Intersci Conf Antimicrob Agents and Chemother (ICAAC), 

Oct 17-20, 1993, New Orleans, LA, American Society of 

Microbiology, session 131, abstract 1432. 

13. Testerman TL, Gerster JF, Imbertson LM et al: Cytokine 

induction by the immunomodulators imiquimod and S-27609.

J Leukocyte Biol 1995; 58:365-372. 

14. Tygrett LT, Li X, Tomai MA et al: 

Imidazoquinolinamines, a new class of immunomodulating 

drugs, are direct B cell mitogens (abstract). FASEB J 

1996; 10:A1461. 

15. Weeks CE & Gibson SJ: Induction of interferon and other

cytokines by imiquimod and its hydroxylated metabolite 

R-842 in human blood cells in vitro. J Interferon Res 

1994; 14:81-85. 

16. Witt PL, Ritch PS, Reding D et al: Phase I trial of an 

oral immunomodulator and interferon inducer in cancer 

patients. Cancer Res 1993; 53: 5176-5180. 

7.0 AUTHOR INFORMATION 

Original publication: 03/97 

Most recent revision: 12/97 

DRUG EVALUATION MONOGRAPHS

Topic: IMIQUIMOD

List of contributors: 

1. DRUGDEX(R) Editorial Staff 

For further information on contributing authors, 

see editorial board listings. 

(c)1974-1998 Micromedex Inc. - All rights reserved - Vol. 96 Exp. 30/06/98

=====================================================================

DATA-MÉDICOS/DERMAGIC-EXPRESS No (8) 25/10/98 DR. JOSE LAPENTA R. DERMATÓLOGO

=====================================================================

Produced by Dr. José Lapenta R. Dermatologist
Venezuela 1.998-2.024

Producido por Dr. José Lapenta R. Dermatólogo Venezuela 1.998-2.0024

Tlf: 0414-2976087 - 04127766810